Introduction. Since 1999 continuous glucose monitoring (CGM) has been used to measure the amount of glucose in the interstitial fluid. CGM is crucial when it comes to developing the ambulatory glucose profile and giving information on time spent in range (TIR), percentage of time spent above and below range, as well as variability. Discussion. It was in 1992 that Campbell et al. first described white coat hyperglycaemia, who explained it as patients having elevated blood glucose levels in a clinician's office or laboratory and normal glucose levels obtained by self-monitoring. Prior to the introduction of CGM, white coat hyperglycaemia was described as the discrepancy in the levels of office glucose and self-monitoring blood glucose (SMBG). Nowadays, it may be said that a patient has white coat hyperglycaemia when they have elevated office levels and normal SMBG levels or TIR above 70% on CGM. Recognising white coat hyperglycaemia is of crucial importance for treatment as its intensification based on office glycaemia alone can lead to episodes of hypoglycaemia and a potentially lethal outcome. Should comparison be made with arterial hypertension and ambulatory blood pressure monitoring (ABPM), CGM may provide several other options: 1) masked hyperglycaemia; 2) isolated nocturnal hyperglycaemia. Conclusion. It seems logical that CGM can be used for diagnosing white coat hyperglycaemia and possibly some (new) entities. Nonetheless, the clinical significance of all these entities can only be discussed after conducting adequately designed randomised clinical trials, which we would strongly encourage.
References
1.
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Supplement_1):S73–84.
2.
Rybicka M, Krysiak R, Okopień B. The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia. Endokrynol Pol. 2011;62(3):276–84.
3.
Hui P, Zhao L, Xie Y, Wei X, Ma W, Wang J, et al. Nocturnal Hypoxemia Causes Hyperglycemia in Patients With Obstructive Sleep Apnea and Type 2 Diabetes Mellitus. The American Journal of the Medical Sciences. 2016;351(2):160–8.
4.
Stojanovic M, Deljanin-Ilic M, Ilic S, Ilic B. Isolated nocturnal hypertension: an unsolved problem—when to start treatment and how low should we go? Journal of Human Hypertension. 2020;34(10):739–40.
5.
Lardinois CK. “White coat” hyperglycemia. Archives of Family Medicine. 1994;3(5):461–4.
6.
Akirov A, Diker-Cohen T, Masri-Iraqi H, Shimon I. High Glucose Variability Increases Mortality Risk in Hospitalized Patients. The Journal of Clinical Endocrinology & Metabolism. 2017;102(7):2230–41.
7.
Rand JS, Kinnaird E, Baglioni A, Blackshaw J, Priest J. Acute Stress Hyperglycemia in Cats Is Associated with Struggling and Increased Concentrations of Lactate and Norepinephrine. Journal of Veterinary Internal Medicine. 2002;16(2):123–32.
8.
Benmoussa JA, Clarke M, Bloomfield D. White Coat Hyperglycemia: The Forgotten Syndrome. Journal of Clinical Medicine Research. 2016;8(8):567–8.
9.
Stojanovic M. The treatment of masked (uncontrolled) hypertension — Should psychiatrists be involved? The European Journal of Psychiatry. 2021;35(3):202–3.
10.
Bloomfield DA, Park A. Decoding white coat hypertension. World Journal of Clinical Cases. 2017;5(3):82.
11.
Campbell LV, Ashwell SM, Borkman M, Chisholm DJ. White coat hyperglycaemia: disparity between diabetes clinic and home blood glucose concentrations. BMJ. 1992;305(6863):1194–6.
12.
Williams B, Mancia G. Ten Commandments of the 2018 ESC/ESH HTN Guidelines on Hypertension in Adults. European Heart Journal. 2018;39(33):3007–8.
13.
Modi AC, Ingerski LM, Rausch JR, Glauser TA, Drotar D. White Coat Adherence over the First Year of Therapy in Pediatric Epilepsy. The Journal of Pediatrics. 2012;161(4):695-699.e1.
14.
Zueger T, Gloor M, Lehmann V, Melmer A, Kraus M, Feuerriegel S, et al. White coat adherence effect on glucose control in adult individuals with diabetes. Diabetes Research and Clinical Practice. 2020;168:108392.
15.
Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400–5.
16.
Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. Journal of Diabetes Science and Technology. 2019;13(4):614–26.
17.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603.
18.
Messaaoui A, Tenoutasse S, Crenier L. Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. Diabetes Technology & Therapeutics. 2019;21(6):329–35.
19.
Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet. 2016;388(10057):2254–63.
20.
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA. 2017;317(4):379.
21.
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Supplement_1):S85–99.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
